Our data suggest that targeting the intracellular domain of BST2 in IFN-mediated inflammatory and autoimmune disorders might attenuate disease by redirecting TH17 cell responses toward a non-pathogenic phenotype. This evidence concerns the gene IFNA1 and autoimmune disease.